Tomer Kariv, a Director, acquired 298,431 Common Shares on an indirect ownership basis for registered holder Pontifax (Cayman) IV Limited, 331,429 Common Shares on an indirect ownership basis for registered holder Pontifax (China) IV Limited Partnership, 612,997 Common Shares on an indirect ownership basis for registered holder Pontifax (Israel) IV Limited and 185,714 Common Shares on an indirect ownership basis for registered holder Pontifax Late Stage Fund L.P. at a price of US$1.40 through a prospectus or prospectus exempt offering on December 17th, 2018. This represents a $2,679,799 investment into the company's shares and an account share holdings change of 62.2%.
VBI Vaccines is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.
VBI Vaccines Inc. is a development-stage biotechnology company. The Company's principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company's subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda).
No Comments